Is there a role for PET/CT with esophagogastric junction adenocarcinoma?

Abstract

The value of 18F-FDG PET/CT in the initial diagnosis and in the locoregional staging of esophagogastric junction adenocarcinoma is not fully established. However, 18F-FDG PET/CT is widely accepted as the best modality for identification of suspected metastases in staging of the disease. Results published in the literature suggest that 18F-FDG PET/CT may provide useful information for response assessment to neoadjuvancy and to differentiate responding and nonresponding tumors. We review the potential role of 18F-FDG PET/CT imaging in staging, restaging, and prognostic value after chemoradiation therapy in esophagogastric junction adenocarcinoma.

• Authors: David Fuster, Maria Mayoral, Domenico Rubello, Estela Pineda, Gloria Fernández-Esparrach, Mario Pagès, Patrick M Colletti, Francesca Pons
• Journal: Clinical nuclear medicine (Clin Nucl Med) Vol. 40 Issue 3 Pg. e201-7 (Mar 2015) ISSN: 1536-0229 [Electronic] United States
• PMID: 25546207 (Publication Type: Journal Article, Review)

Chemical References

• Radiopharmaceuticals
• Fluorodeoxyglucose F18

Topics

• Adenocarcinoma (diagnostic imaging)
• Esophageal Neoplasms (diagnostic imaging)
• Esophagogastric Junction (diagnostic imaging)
• Fluorodeoxyglucose F18
• Humans
• Multimodal Imaging
• Positron-Emission Tomography
• Radiopharmaceuticals
• Stomach Neoplasms (diagnostic imaging)
• Tomography, X-Ray Computed